ICONAN 2019 conference will gather high-profile Nanomedicine and Nanobiotechnology experts to deliver plenary speeches:
Prof. Simona Mura
Institut Galien Paris-Sud, France
After a Master Degree in Chemistry and Pharmaceutical Technology at the University of Cagliari (Italy), Dr Mura has been awarded her PhD in Chemistry and Technology of Drug in 2009 at the same university working on the design and in vitro evaluation of novel vesicular systems for the topical delivery of drugs. In 2008 she joined the group of Prof. Elias Fattal (Galien Institute, UMR CNRS 8612) at the University Paris-Sud (France), as a post-doctoral research assistant to study the lung toxicity of biodegradable nanoparticles designed for pulmonary drug administration.
In 2011, she has been appointed Associate professor in the same University within the framework of the «CNRS-Higher Education chairs» program (Chaires d ‘excellence CNRS) and she has integrated the team of Patrick Couvreur. Since 2015 she is also regularly hosted as Visiting Associate professor at the University of Osaka (Japan). Her research focuses on the design of biomimetic drug delivery systems and the construction of in vitro and in vivo models for a relevant preclinical assessment of the therapeutic efficacy of nanomedicines. She is (co)author of 50 peer review articles in international journals, 4 book chapters and co-editor of 1 book. Dr Mura has also been appointed Junior member of the prestigious Institut Universitaire de France (IUF) in 2017.
Prof. Ernst Wagner
LMU Munich, Germany
Ernst Wagner is full professor of Pharmaceutical Biotechnology at Ludwig-Maximilians-Universität (LMU) of Munich since 2001 and member of Center for Nanoscience (CeNS). He coordinates the area of ‘Biomedical Nanotechnologies’ of the Cluster of Excellence ‘Nanosystems Initiative Munich (NIM)’. Dr. Wagner received a Ph.D. in Organic Chemistry from the Technical University of Vienna. After a postdoctoral stay at the ETH in Zurich, he became group leader at the Institute of Molecular Pathology and at the Vienna University Biocenter, developing synthetic gene transfer systems. In parallel, 1992-2001 he was Director for Cancer Vaccines at Boehringer Ingelheim Austria, where he developed the first-in-world polymer-based clinical gene therapy study in 1994.
Talk title: Sequence-defined carriers for optimizing nucleic acid nanomedicines by chemical evolution
Prof. Andrew Owen
University of Liverpool, UK
Andrew Owen is Professor of Molecular and Clinical Pharmacology at the University of Liverpool, UK. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, and a fellow of the Learned Society of Wales. His clinical and basic research focuses on understanding mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics. A major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of technologies to clinical applications for oral and long-acting drug delivery. His ongoing research portfolio is funded by NIH, USAID, EPSRC, EC and pharmaceutical and charitable agencies. He has published over 200 publications, is co-inventor of patents relating to drug delivery and is a co-founder of Tandem Nano Ltd (www.tandemnano.com) and PKTK (www.PKTK.co.uk). Professor Owen also co-leads the UK contribution to the European Nanomedicine Characterisation Laboratory (www.EUNCL.eu) and the modeling core for the Long-acting/Extended-release Antiretroviral resource Program (www.LEAPresources.org). He is also an Editor in Chief for the Journal of Interdisciplinary Nanomedicine (www.JOINjournal.com).
Talk title: Opportunities and challenges for long-acting drug delivery: the changing paradigm for chronic disease therapy
Dr. Cristianne Rijcken
Chief Scientific Officer and a Founder of Cristal Therapeutics, The Netherlands
Dr. Cristianne Rijcken is Chief Scientific Officer and a Founder of Cristal Therapeutics. Dr. Rijcken’s PhD thesis provided a strong basis for Cristal Therapeutics and she was awarded multiple grants and prizes including the Simon Stevin Gezel Award in 2008 and the Knowledge for Growth Inspiring Young Scientist Award in 2014. She has authored over 30 scientific publications and is named on all Cristal Therapeutics’ patents and patent applications. In recognition of Dr Rijcken’s innovative approach, strength in translational research and her entrepreneurial attitude, she was awarded the Limburg Businesswoman of the Year in 2017. Cristianne is pharmacist by training and holds a PhD degree in Pharmaceutics from Utrecht University, The Netherlands.
Dr. Roy van Der Meel
Eindhoven University of Technology, The Netherlands
Roy van der Meel obtained his PhD at Utrecht University under direction of Gert Storm and Wim Hennink. He conducted postdoctoral research in the labs of Raymond Schiffelers at the University Medical Center Utrecht and Pieter Cullis at the University of British Columbia, funded by a Marie Skłodowska-Curie Action and a Veni grant from the Netherlands Organization for Scientific Research. Roy is currently appointed as Assistant Professor at the Eindhoven University of Technology’s Biomedical Engineering department where he heads the Precision Medicine group under direction of Willem Mulder. His group’s research is focused on developing nanotherapeutics to regulate the immune response in a highly precise manner.
Dr. Matthias Barz
AK Barz Lab, Johannes Gutenberg University Mainz, Germany
Dr. Matthias Barz was born in 1982 in Frankfurt Main, Germany. After finishing high school he studied chemistry at the Johannes Gutenberg-University Mainz (Germany) and Seoul National University (South Korea), received a diploma degree in chemistry in 2006 and a PhD in polymer chemistry from the Johannes Gutenberg-University Mainz (Germany) working under the supervision of Prof. R. Zentel. After finishing his PhD he worked in the laboratory of Dr. Maria J. Vicent at the CIPF in 2010 as a postdoctoral researcher. In 2011 he returned briefly to Mainz as a senior researcher before joining the group of Prof. T. Kirchhausen at Boston Children’s Hospital, Harvard Medical School (endocytosis of nanomedicines). In 2013 he became independent junior research group leader and started his habilitation at the Institute of Organic Chemistry at the Johannes Gutenberg-University Mainz (Germany). In the end of 2016 he received the venia legendi for organic chemistry and became lecturer at the JGU. He is currently head of the graduate center and member of the steering committee of the collaborative research center for nanoparticle based cancer immune therapy (CRC 1066) and member of an H2020 consortium (Click-It) and an ITN (PET-AlphaSy).
Prof. Dario Neri
ETH Zürich, Switzerland
Dario Neri was born in Rome on 1 May 1963 but grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a Ph.D. in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral research internship (1992-1996) at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter (Nobel Prize Chemistry 2018), he became a professor at ETH Zürich in 1996.
Dario Neri is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich. The research of the Neri group focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders and on the development of DNA-encoded chemical libraries.
Dario Neri is a co-founder of Philogen (www.philogen.com<http://www.
Dario Neri has published 400 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011, of the Phoenix Prize 2014 and of an ERC Advanced Grant in 2015.
Talk title: From encoded combinatorial libraries to targeted therapeutics
Prof. Paolo Decuzzi
Italian Institute of Technology, Italy
Paolo Decuzzi is a senior researcher and director of the Laboratory of Nanotechnology for Precision Medicine at the Italian Institute of Technology in Genova – Italy. Dr. Decuzzi earned his M.Sc. degree in Mechanical Engineering from the Politecnico di Bari (Italy) in 1997 and his Ph.D. degree in Mechanical Engineering from the University of Naples – Federico II (Italy) in 2000, with a thesis on friction and adhesion at the nanoscale. In 2002, he was nominated Assistant Professor of Machine Design at the Politecnico di Bari and, in 2005, he became Associate Professor in the School of Medicine of the University ‘Magna Graecia’. There, he co-founded BioNEM – the laboratory of BioNanotechnology and Engineering for Medicine – one of the first nano-engineering laboratories built in a School of Medicine. In October 2007, he joined The University of Texas Health Science Center in Houston as an Associate Professor of Biomedical Engineering. In October 2010, he moved to the Houston Methodist Hospital where he served as a Professor of Biomedical Engineering till July 2015. There, he founded the Center for the Rational Design of Multifunctional Nanoconstructs, with the financial support of the Cancer Prevention and Research Center of Texas and the US National Cancer Institute; and served first as the co-chair of the Nanomedicine Department and then as the interim chair of the Translational Imaging Department. In July 2014, Dr. Decuzzi was awarded a 5-year European Research Council “Consolidator Grant” to design, synthesize and develop nanoconstructs for imaging and therapy in brain cancer.
Dr. Decuzzi has been visiting scientist at the Department of Theoretical and Applied Mechanics at the University of Michigan – Ann Arbor (1998, 1999 and 2001); and visiting professor at the Princeton Material Institute – Princeton (2003); the Heart and Lung Institute at the Ohio State University (2003 and 2004); the University of Texas Health Science Center (2006).
Dr. Decuzzi has published over 150 papers in international peer-reviewed journals, international conferences and book chapters. He holds over 5 patents in the field of Nanomedicine. He co-founded NEMB – NanoEngineering for Medicine and Biology – committee of the American Society for Mechanical Engineers and is involved in multiple dissemination activities to foster the collaboration between biomedical scientists and engineers. He serves on multiple NIH, NSF, ESF, and Italian Government study sections and his research activity is primarily supported by NIH, DOD, CPRIT in USA; ESF and ERC in EU.
Decuzzi’s lab mission is to
- rationally design polymeric nanoconstructs for multi-modal imaging and combination therapy in cancer, cardiovascular and neurological diseases;
- fabricate microfluidic chips for the rapid screening of novel molecular and nano-based therapeutic agents;
- develop multi-scale, hierarchical computational models for predicting the transport and therapeutic efficacy of nanoconstructs;
- organize dissemination activities at the interface between engineering and biomedical sciences; and
- promote the professional development of lab members in a highly multi-disciplinary environment.
Talk title: Tuning particle deformability in drug delivery systems
Dr. Bart Metselaar
Enceladus Pharmaceuticals / RWTH Aachen University, Germany
My name is Josbert M. Metselaar, born in Rotterdam July 6th, 1971. I obtained an MSc degree in Pharmaceutical Sciences in 1995 and a PharmD degree in 1998, both at Utrecht University. During my study, I completed a research internship in pharmacology and PK/PD at the Dept of Pharmaceutics, University of Florida, US. In 1999 I started a Ph.D. at the Dept of Immunology and the Dept of Pharmaceutics in Utrecht where I studied novel targeted formulations of anti-inflammatory medicines.
After completing my Ph.D. in 2003 and a Post Doc fellowship in 2005, I decided to translate part of my accomplishments into investigational medicinal products by starting a company named Enceladus, with which I raised more than 6 million Euros funding over the years. With these investments and additional non-equity funding I successfully performed a series of preclinical and clinical development projects on three liposomal products, including 6 clinical trials.
In 2012 I took a part-time academic position in the group of Targeted Therapeutics at the University of Twente, where I worked on drug carrier design and formulation development in the field of advanced drug delivery for inflammation, atherosclerosis, and cancer. In 2015 I took a position at the Dept. of Experimental Molecular Imaging at the RWTH Aachen University Clinic in Germany, where I especially focus on translational aspects of nanomedicine for cancer treatment and diagnosis (imaging).
Besides my academic career, I have more than 12 years of experience in industrial drug product development, covering all pharmaceutical development aspects as well as preclinical and clinical studies. My relevant areas of expertise include formulation design and development for advanced drug delivery, quality control, nanomedicine pharmacokinetics, biodistribution and safety studies, and clinical study design and implementation.
Dr. Maria Vicent
Centro Investigacion Principe Felipe, Spain
Dr. Thomas Bein
LMU Munich, Germany
Prof. Raymond Schiffelers
University Medical Center Utrecht, The Netherlands
Prof. Giuseppe Battaglia
University College London, UK
Prof. Marcelle Machluf
Faculty of Biotechnology and Food Engineering, TECHNION, Israel
Dr. Alexander N. Zelikin
Aarhus University, Denmark
Dr. Mattias Björnmalm
Imperial College London, UK
Prof. Marianne Ashford
Innovative Medicines Biotech Unit, AstraZeneca, UK
More plenary speakers and more information are coming soon.